Select All | Select None
Login failed. Please try again.
Forgot your password?
Log in with Facebook
Log in with Google
You can now keep track of new articles from European Journal of Cancer Supplements on your personalized homepage!
The third-generation aromatase inhibitors (AIs) are gradually displacing tamoxifen as the preferred adjuvant endocrine treatment for hormone-receptor-positive early breast cancer in postmenopausal women, having demonstrated superior efficacy in clinical trials. However, for the AIs to gain...
In early breast cancer, adjuvant therapy significantly reduces the risk of recurrence after complete surgical resection of the tumor mass. For over a decade, 5 years of adjuvant endocrine therapy with the selective estrogen receptor modulator tamoxifen has been the gold standard in...
The selective estrogen-receptor modulator, tamoxifen, has been the mainstay of adjuvant endocrine therapy for several decades, significantly improving outcomes for numerous women with hormone-receptor-positive (HR+) early breast cancer. However, tamoxifen is associated with acquired resistance:...
results per page
Save this article to read later. You can see your Read Later on your DeepDyve homepage.
To save an article, log in first, or sign up for a DeepDyve account if you don't already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don't already have one.
Read and print from thousands of top scholarly journals.
Sign up with Facebook
Sign up with Google
Already have an account? Log in
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don't already have one.